Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.5M Sell
53,615
-2
-0% -$430 0.63% 20
2026
Q1
$11.7M Sell
53,617
-629
-1% -$140K 0.65% 20
2025
Q4
$12.4M Sell
54,246
-77
-0.1% -$17.5K 0.67% 17
2025
Q3
$12.6M Buy
54,323
+79
+0.1% +$16.1K 0.73% 17
2025
Q2
$10.1M Sell
54,244
-4,280
-7% -$795K 0.63% 16
2025
Q1
$12.3M Sell
58,524
-9
-0% -$1.75K 0.87% 14
2024
Q4
$10.4M Sell
58,533
-2,932
-5% -$539K 0.73% 15
2024
Q3
$12.1M Buy
61,465
+6,578
+12% +$1.23M 0.93% 13
2024
Q2
$9.41M Sell
54,887
-8,162
-13% -$1.35M 0.77% 13
2024
Q1
$11.5M Buy
63,049
+7,144
+13% +$1.23M 0.92% 14
2023
Q4
$8.66M Buy
55,905
+603
+1% +$87.9K 0.89% 13
2023
Q3
$8.24M Buy
55,302
+3,394
+7% +$498K 0.93% 13
2023
Q2
$6.99M Sell
51,908
-209
-0.4% -$30.6K 0.77% 13
2023
Q1
$8.31M Sell
52,117
-85
-0.2% -$13K 0.96% 12
2022
Q4
$8.44M Buy
52,202
+54
+0.1% +$8.28K 0.95% 12
2022
Q3
$7M Sell
52,148
-2,488
-5% -$357K 0.9% 13
2022
Q2
$8.37M Sell
54,636
-500
-0.9% -$76.4K 0.98% 14
2022
Q1
$8.94M Buy
55,136
+16,445
+43% +$2.39M 0.84% 17
2021
Q4
$5.24M Buy
38,691
+167
+0.4% +$19.7K 0.62% 22
2021
Q3
$4.16M Sell
38,524
-2,940
-7% -$336K 0.34% 28
2021
Q2
$4.67M Sell
41,464
-343
-0.8% -$38.6K 0.37% 24
2021
Q1
$4.52M Buy
41,807
+26
+0.1% +$2.78K 0.37% 29
2020
Q4
$4.48M Buy
41,781
+84
+0.2% +$8.07K 0.37% 25
2020
Q3
$3.65M Buy
41,697
+3,267
+9% +$308K 0.31% 27
2020
Q2
$3.77M Sell
38,430
-2,891
-7% -$255K 0.48% 19
2020
Q1
$3.15M Buy
41,321
+315
+0.8% +$26.8K 0.47% 25
2019
Q4
$3.63M Sell
41,006
-26
-0.1% -$2.16K 0.4% 28
2019
Q3
$3.11M Buy
41,032
+41
+0.1% +$2.81K 0.47% 19
2019
Q2
$2.98M Hold
40,991
0.48% 23
2019
Q1
$3.3M Hold
40,991
0.43% 37
2018
Q4
$3.78M Hold
40,991
0.5% 29
2018
Q3
$3.88M Buy
40,991
+700
+2% +$66.4K 0.56% 19
2018
Q2
$3.73M Buy
40,291
+36,070
+855% +$3.52M 0.63% 16
2018
Q1
$400K Buy
+4,221
New +$464K 0.07% 62
2016
Q3
Sell
-4,150
Closed -$257K 78
2016
Q2
$257K Buy
+4,150
New +$253K 0.04% 60

Other funds holding ABBV

BBR Partners's ABBV Position: Q2 2026 in Review

BBR Partners reduced its AbbVie (ABBV) stake by 0% in Q2 2026, selling an estimated $430 and leaving 53,615 shares worth $13.5M. The position accounts for 0.63% of the portfolio, ranked #20.

BBR Partners first reported a position in ABBV in Q2 2016 and has held it in 35 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • BBR Partners held 53,615 shares of AbbVie worth $13.5M as of Q2 2026.
  • BBR Partners sold 2 AbbVie shares in Q2 2026, an estimated $430.
  • AbbVie made up 0.63% of BBR Partners's portfolio in Q2 2026, its #20 holding.
  • BBR Partners first reported a position in AbbVie in Q2 2016 and has held it in 35 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on BBR Partners's 13F filing for Q2 2026, filed 11 Aug 2026.